Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story?
Monte Rosa Therapeutics announced a past supply agreement with Johnson & Johnson under which Johnson & Johnson will provide ERLEADA (apalutamide) for a Monte Rosa–sponsored Phase 2 trial evaluating MRT-2359 in patients with metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor mutations, with study initiation planned for the third quarter of 2026.
This collaboration builds on encouraging early clinical data for MRT-2359 plus enzalutamide and highlights growing...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.